LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice

Human Molecular Genetics

Volumn 20, Issue 21, 2011, Pages 4209-4223

  Herzig, Martin C ^a   Kolly, Carine ^a   Persohn, Elke ^a   Theil, Diethilde ^a   Schweizer, Tatjana ^a   Hafner, Thomas ^a   Stemmelen, Christine ^a   Troxler, Thomas J ^a   Schmid, Peter ^a   Danner, Simone ^a   Schnell, Christian R ^a   Mueller, Matthias ^a   Kinzel, Bernd ^a   Grevot, Armelle ^a   Bolognani, Federico ^a   Stirn, Martina ^a   Kuhn, Rainer R ^a   Kaupmann, Klemens ^a   Van der putten, P Herman ^a   Rovelli, Giorgio ^a   Shimshek, Derya R ^a   more..

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2; MUTANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HYPERTENSION; KIDNEY DISEASE; KIDNEY PROXIMAL TUBULE; KNOCKOUT MOUSE; LAMELLAR BODY; LUNG ALVEOLUS CELL TYPE 2; LUNG DISEASE; LYSOSOME; MALE; MOUSE; MOUSE MUTANT; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ANIMALS; BLOOD PRESSURE; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; ENZYME STABILITY; HOMEOSTASIS; KIDNEY; KIDNEY TUBULES, PROXIMAL; LUNG; LYSOSOMES; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MOTOR ACTIVITY; PNEUMOCYTES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

MUS;

EID: 80053968304     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr348     Document Type: Article

References (62)

1. Esposito, E., Di Matteo, V. and Di Giovanni, G. (2007) Death in the substantia nigra: a motor tragedy. Expert Rev. Neurother., 7, 677-697.
2. Healy, D.G., Falchi, M., O'Sullivan, S.S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C.P., Goldwurm, S. et al. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol., 7, 583-590.
3. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44, 601-607.
4. Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A.M., Khan, N. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron, 44, 595-600.
5. Simon-Sanchez, J., Schulte, C., Bras, J.M., Sharma, M., Gibbs, J.R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S.W., Hernandez, D.G. et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet., 41, 1308-1312.
6. Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A. et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet., 41, 1303-1307.
7. International Parkinson Disease Genomics Consortium. (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet, 377, 641-649.
8. Cookson, M.R. (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat. Rev. Neurosci., 11, 791-797.
9. Barrett, J.C., Hansoul, S., Nicolae, D.L., Cho, J.H., Duerr, R.H., Rioux, J.D., Brant, S.R., Silverberg, M.S., Taylor, K.D., Barmada, M.M. et al. (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet., 40, 955-962.
10. Looyenga, B.D., Furge, K.A., Dykema, K.J., Koeman, J., Swiatek, P.J., Giordano, T.J., West, A.B., Resau, J.H., Teh, B.T. and MacKeigan, J.P. (2011) Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc. Natl Acad. Sci. USA, 108, 1439-1444.
11. Anand, V.S. and Braithwaite, S.P. (2009) LRRK2 in Parkinson's disease: biochemical functions. FEBS J., 276, 6428-6435.
12. West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W.W., Ross, C.A., Dawson, V.L. and Dawson, T.M. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA, 102, 16842-16847.
13. Kumar, A., Greggio, E., Beilina, A., Kaganovich, A., Chan, D., Taymans, J.M., Wolozin, B. and Cookson, M.R. (2010) The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS ONE, 5, e8730.
14. Dusonchet, J., Kochubey, O., Stafa, K., Young, S.M. Jr, Zufferey, R., Moore, D.J., Schneider, B.L. and Aebischer, P. (2011) A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J. Neurosci., 31, 907-912.
15. Iaccarino, C., Crosio, C., Vitale, C., Sanna, G., Carri, M.T. and Barone, P. (2007) Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum. Mol. Genet., 16, 1319-1326.
16. Smith, W.W., Pei, Z., Jiang, H., Dawson, V.L., Dawson, T.M. and Ross, C.A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci., 9, 1231-1233.
17. Lee, B.D., Shin, J.H., VanKampen, J., Petrucelli, L., West, A.B., Ko, H.S., Lee, Y.I., Maguire-Zeiss, K.A., Bowers, W.J., Federoff, H.J. et al. (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat. Med., 16, 998-1000.
18. Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, R.J. 3rd and Shen, J. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc. Natl Acad. Sci. USA, 107, 9879-9884.
19. Finch, C.E. (1993) Neuron atrophy during aging: programmed or sporadic? Trends Neurosci., 16, 104-110.
20. Reichel, W. (1968) Lipofuscin pigment accumulation and distribution in five rat organs as a function of age. J. Gerontol., 23, 145-153.
21. Ochs, M. (2010) The closer we look the more we see? Quantitative microscopic analysis of the pulmonary surfactant system. Cell. Physiol. Biochem., 25, 27-40.
22. Zhao, C.Z., Fang, X.C., Wang, D., Tang, F.D. and Wang, X.D. (2010) Involvement of type II pneumocytes in the pathogenesis of chronic obstructive pulmonary disease. Respir. Med., 104, 1391-1395.
23. Weaver, T.E., Na, C.L. and Stahlman, M. (2002) Biogenesis of lamellar bodies, lysosome-related organelles involved in storage and secretion of pulmonary surfactant. Semin. Cell Dev. Biol., 13, 263-270.
24. Cruz, D.N., Simon, D.B., Nelson-Williams, C., Farhi, A., Finberg, K., Burleson, L., Gill, J.R. and Lifton, R.P. (2001) Mutations in the Na-Cl cotransporter reduce blood pressure in humans. Hypertension, 37, 1458-1464.
25. Wilson, F.H., Disse-Nicodeme, S., Choate, K.A., Ishikawa, K., Nelson-Williams, C., Desitter, I., Gunel, M., Milford, D.V., Lipkin, G.W., Achard, J.M. et al. (2001) Human hypertension caused by mutations in WNK kinases. Science, 293, 1107-1112.
26. Lifton, R.P., Gharavi, A.G. and Geller, D.S. (2001) Molecular mechanisms of human hypertension. Cell, 104, 545-556.
27. Alegre-Abarrategui, J., Christian, H., Lufino, M.M., Mutihac, R., Venda, L.L., Ansorge, O. and Wade-Martins, R. (2009) LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet., 18, 4022-4034.
28. Plowey, E.D., Cherra, S.J. 3rd, Liu, Y.J. and Chu, C.T. (2008) Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem., 105, 1048-1056.
29. Xiong, Y., Coombes, C.E., Kilaru, A., Li, X., Gitler, A.D., Bowers, W.J., Dawson, V.L., Dawson, T.M. and Moore, D.J. (2010) GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet., 6, e1000902.
30. Wong, E. and Cuervo, A.M. (2010) Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci., 13, 805-811.
31. Chen, J.K., Chen, J., Neilson, E.G. and Harris, R.C. (2005) Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J. Am. Soc. Nephrol., 16, 1384-1391.
32. Kasinath, B.S., Feliers, D., Sataranatarajan, K., Ghosh Choudhury, G., Lee, M.J. and Mariappan, M.M. (2009) Regulation of mRNA translation in renal physiology and disease. Am. J. Physiol. Renal. Physiol., 297, F1153-F1165.
33. Franch, H.A. (2002) Pathways of proteolysis affecting renal cell growth. Curr. Opin. Nephrol. Hypertens., 11, 445-450.
34. Imai, Y., Gehrke, S., Wang, H.Q., Takahashi, R., Hasegawa, K., Oota, E. and Lu, B. (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J., 27, 2432-2443.
35. Gehrke, S., Imai, Y., Sokol, N. and Lu, B. (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature, 466, 637-641.
36. Huizing, M., Helip-Wooley, A., Westbroek, W., Gunay-Aygun, M. and Gahl, W.A. (2008) Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu. Rev. Genomics Hum. Genet., 9, 359-386.
37. Young, B. and Heath, J.W. (2002) Wheater's Functional Histology: A Text and Colour Atlas. Elsevier Science.
38. Ghadially, F.N. (1975) Ultrastructural Pathology of the Cell: A Text and Atlas of Physiological and Pathological Alterations in Cell Fine Structure. Butterworths, London.
39. Goldstein, D.S., Imrich, R., Peckham, E., Holmes, C., Lopez, G., Crews, C., Hardy, J., Singleton, A. and Hallett, M. (2007) Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation. Neurology, 69, 1580-1584.
40. Jung, T., Bader, N. and Grune, T. (2007) Lipofuscin: formation, distribution, and metabolic consequences. Ann. N Y Acad. Sci., 1119,97-111.
41. Zechel, S., Meinhardt, A., Unsicker, K. and von Bohlen Und Halbach, O. (2010) Expression of leucine-rich-repeat-kinase 2 (LRRK2) during embryonic development. Int. J. Dev. Neurosci., 28, 391-399.
42. Christensen, E.I., Verroust, P.J. and Nielsen, R. (2009) Receptor-mediated endocytosis in renal proximal tubule. Pflugers Arch., 458, 1039-1048.
43. MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K. and Abeliovich, A. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron, 52, 587-593.
44. Shin, N., Jeong, H., Kwon, J., Heo, H.Y., Kwon, J.J., Yun, H.J., Kim, C.H., Han, B.S., Tong, Y., Shen, J. et al. (2008) LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res., 314, 2055-2065.
45. Biskup, S., Moore, D.J., Celsi, F., Higashi, S., West, A.B., Andrabi, S.A., Kurkinen, K., Yu, S.W., Savitt, J.M., Waldvogel, H.J. et al. (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol., 60, 557-569.
46. Higashi, S., Moore, D.J., Yamamoto, R., Minegishi, M., Sato, K., Togo, T., Katsuse, O., Uchikado, H., Furukawa, Y., Hino, H. et al. (2009) Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. J. Neuropathol. Exp. Neurol., 68, 994-1005.
47. Neumann, J., Bras, J., Deas, E., O'Sullivan, S.S., Parkkinen, L., Lachmann, R.H., Li, A., Holton, J., Guerreiro, R., Paudel, R. et al. (2009) Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain, 132, 1783-1794.
48. Nishioka, K., Vilarino-Guell, C., Cobb, S.A., Kachergus, J.M., Ross, O.A., Wider, C., Gibson, R.A., Hentati, F. and Farrer, M.J. (2010) Glucocerebrosidase mutations are not a common risk factor for Parkinson disease in North Africa. Neurosci. Lett., 477, 57-60.
49. Ichimura, Y. and Komatsu, M. (2011) Pathophysiological role of autophagy: lesson from autophagy-deficient mouse models. Exp. Anim., 60, 329-345.
50. Panasyuk, G., Nemazanyy, I., Zhyvoloup, A., Filonenko, V., Davies, D., Robson, M., Pedley, R.B., Waterfield, M. and Gout, I. (2009) mTORbeta splicing isoform promotes cell proliferation and tumorigenesis. J. Biol. Chem., 284, 30807-30814.
51. Vitari, A.C., Deak, M., Collins, B.J., Morrice, N., Prescott, A.R., Phelan, A., Humphreys, S. and Alessi, D.R. (2004) WNK1, the kinase mutated in an inherited high-blood-pressure syndrome, is a novel PKB (protein kinase B)/Akt substrate. Biochem. J., 378, 257-268.
52. Nembrini, C., Kisielow, J., Shamshiev, A.T., Tortola, L., Coyle, A.J., Kopf, M. and Marsland, B.J. (2009) The kinase activity of Rip2 determines its stability and consequently Nod1-and Nod2-mediated immune responses. J. Biol. Chem., 284, 19183-19188.
53. Meylan, E. and Tschopp, J. (2005) The RIP kinases: crucial integrators of cellular stress. Trends Biochem. Sci., 30, 151-159.
54. Li, X., Wang, Q.J., Pan, N., Lee, S., Zhao, Y., Chait, B.T. and Yue, Z. (2011) Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS ONE, 6,e17153.
55. Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., Lee, J.D., Patricelli, M.P., Nomanbhoy, T.K., Alessi, D.R. et al. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat. Chem. Biol., 7, 203-205.
56. Dzamko, N., Deak, M., Hentati, F., Reith, A.D., Prescott, A.R., Alessi, D.R. and Nichols, R.J. (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem. J., 430, 405-413.
57. Funayama, M., Hasegawa, K., Ohta, E., Kawashima, N., Komiyama, M., Kowa, H., Tsuji, S. and Obata, F. (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol., 57, 918-921.
58. Jaleel, M., Nichols, R.J., Deak, M., Campbell, D.G., Gillardon, F., Knebel, A. and Alessi, D.R. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J., 405, 307-317.
59. Anand, V.S., Reichling, L.J., Lipinski, K., Stochaj, W., Duan, W., Kelleher, K., Pungaliya, P., Brown, E.L., Reinhart, P.H., Somberg, R. et al. (2009) Investigation of leucine-rich repeat kinase 2: enzymological properties and novel assays. FEBS J., 276, 466-478.
60. Ohta, E., Katayama, Y., Kawakami, F., Yamamoto, M., Tajima, K., Maekawa, T., Iida, N., Hattori, S. and Obata, F. (2009) I(2020)T leucine-rich repeat kinase 2, the causative mutant molecule of familial Parkinson's disease, has a higher intracellular degradation rate than the wild-type molecule. Biochem. Biophys. Res. Commun., 390, 710-715.
61. Tucker, K.L., Wang, Y., Dausman, J. and Jaenisch, R. (1997) A transgenic mouse strain expressing four drug-selectable marker genes. Nucleic Acids Res., 25, 3745-3746.
62. Schwenk, F., Baron, U. and Rajewsky, K. (1995) A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res., 23, 5080-5081.